POC脓毒症检测软件为临床医生提供ICU患者病情恶化的早期预警-动脉网

POC Sepsis Detection Software Provides Clinicians with Early Warning of Patient Deterioration in ICU

HospiMedica 等信源发布 2024-08-27 04:28



可切换为仅中文







Sepsis, a severe reaction to infection causing widespread inflammation, can rapidly lead to organ damage and death, making it the primary cause of mortality within hospitals globally, contributing to around 35% of all hospital deaths. The key to combating sepsis lies in its early detection and prompt treatment.

。对抗败血症的关键在于其早期发现和及时治疗。

Although intensive care units (ICUs) generate vast amounts of data, which can make it difficult to spot some signs of patient deterioration in time, these environments are ideally suited for the application of artificial intelligence (AI) technologies. Now, an AI solution offers the potential to improve sepsis care by providing healthcare providers with a powerful tool to identify patients at risk in the Emergency Department (ED) as well as other hospital wards..

尽管重症监护病房（ICU）产生了大量数据，这使得很难及时发现患者病情恶化的迹象，但这些环境非常适合人工智能（AI）技术的应用。现在，人工智能解决方案通过为医疗保健提供者提供强大的工具来识别急诊科（ED）以及其他医院病房的高危患者，从而有可能改善败血症护理。。

AlgoDx (Stockholm, Sweden) has introduced NAVOY CDS, a sepsis detection software using a proprietary algorithm, to support clinicians in identifying sepsis in hospitalized patients, including the ED. Utilizing a machine learning algorithm trained on data from over 60,000 ICU stays, NAVOY can predict the risk of sepsis up to three hours before traditional rule-based scoring systems, thereby facilitating earlier and more accurate clinical responses that can save lives and reduce healthcare expenses..

AlgoDx（瑞典斯德哥尔摩）推出了NAVOY CDS，这是一种使用专有算法的败血症检测软件，用于支持临床医生识别住院患者（包括急诊室）的败血症。利用对60000多名ICU住院患者的数据进行训练的机器学习算法，NAVOY可以在传统的基于规则的评分系统之前三个小时预测败血症的风险，从而促进更早和更准确的临床反应，从而挽救生命并减少医疗费用。。

As a software as a medical device (SaMD), NAVOY continuously analyzes a range of vital signs, lab results, and other critical patient data gathered in the ICU, integrating seamlessly into existing Electronic Health Records (EHR) and Patient Data Management Systems (PDMS). This integration ensures that NAVOY’s predictions are readily accessible, providing clinicians with timely, actionable insights that enable swift interventions.

作为一种医疗设备软件（SaMD），NAVOY不断分析ICU收集的一系列生命体征，实验室结果和其他关键患者数据，并将其无缝集成到现有的电子健康记录（EHR）和患者数据管理系统（PDMS）中。这种整合确保了NAVOY的预测很容易获得，为临床医生提供了及时，可行的见解，从而能够进行快速干预。

With the latest U.S. Food and Drug Administration’s (FDA) 510(k) clearance, AlgoDx is set to extend its reach into the U.S. healthcare market, offering a significant advancement in the fight against hospital-acquired sepsis..

随着美国食品和药物管理局（FDA）510（k）的最新批准，AlgoDx将扩大其在美国医疗保健市场的影响力，在对抗医院获得性败血症方面取得重大进展。。

“Receiving FDA clearance for NAVOY CDS is a testament to our team’s dedication and expertise in developing cutting-edge medical device software for healthcare,” said Andreas Macura, Chief Product Officer at AlgoDx. “We believe that NAVOY CDS has the potential to significantly improve patient outcomes by enabling earlier detection and treatment of sepsis.”.

AlgoDx首席产品官安德烈亚斯·马库拉（AndreasMacura）表示：“获得美国食品和药物管理局（FDA）对NAVOY CDS的批准，证明了我们团队在开发用于医疗保健的尖端医疗器械软件方面的奉献精神和专业技能。”。“我们相信NAVOY CDS有可能通过早期发现和治疗败血症来显着改善患者预后。”。

“This FDA clearance is a pivotal moment for AlgoDx as we expand our presence in the United States,” added Dr. Enrico Petrillo, Chairman of the Board AlgoDx. “It validates our commitment to developing innovative technologies that address critical healthcare challenges. We look forward to bringing NAVOY CDS to health systems nationwide.”.

AlgoDx董事会主席EnricoPetrillo博士补充道：“随着我们扩大在美国的业务，FDA的批准对AlgoDx来说是一个关键时刻。”。“这证明了我们致力于开发创新技术，以应对关键的医疗保健挑战。我们期待着将NAVOY CD带到全国的医疗系统。”。